TTM
$14.8B
YoY change
-6.3%
5Y CAGR
+11.2%
Peak year (FY2022)
$37.5B
Cumulative operating income
$423B
Operating Income history chart for Pfizer (PFE) from 2016 to 2025
Latest: $15.4B
Operating Income growth chart for Pfizer (PFE) from 2016 to 2025
Latest: -6.3%
Operating Income history table for Pfizer (PFE) from 1985 to 2025
| FY2025 | $15.4B | -6.3% | -$1.05B | ||
| FY2024 | $16.5B | +211.5% | +$11.2B | ||
| FY2023 | $5.29B | -85.9% | -$32.3B | ||
| FY2022 | $37.5B | +80.6% | +$16.8B | ||
| FY2021 | $20.8B | +128.9% | +$11.7B | ||
| FY2020 | $9.09B | +21.0% | +$1.57B | ||
| FY2019 | $7.51B | -50.9% | -$7.78B | ||
| FY2018 | $15.3B | +6.2% | +$898M | ||
| FY2017 | $14.4B | +0.8% | +$117M | ||
| FY2016 | $14.3B | +7.4% | +$978M | ||
| FY2015 | $13.3B | -5.2% | -$733M | ||
| FY2014 | $14B | -16.9% | -$2.86B | ||
| FY2013 | $16.9B | -6.4% | -$1.15B | ||
| FY2012 | $18B | -1.9% | -$343M | ||
| FY2011 | $18.4B | +3.7% | +$650M | ||
| FY2010 | $17.7B | +10.8% | +$1.72B | ||
| FY2009 | $16B | -3.7% | -$616M | ||
| FY2008 | $16.6B | +19.4% | +$2.7B | ||
| FY2007 | $13.9B | -7.8% | -$1.17B | ||
| FY2006 | $15.1B | +3.9% | +$563M | ||
| FY2005 | $14.5B | -15.0% | -$2.56B | ||
| FY2004 | $17.1B | +58.2% | +$6.29B | ||
| FY2003 | $10.8B | -12.0% | -$1.48B | ||
| FY2002 | $12.3B | +11.9% | +$1.3B | ||
| FY2001 | $11B | +26.6% | +$2.31B | ||
| FY2000 | $8.67B | +90.6% | +$4.12B | ||
| FY1999 | $4.55B | +26.3% | +$946M | ||
| FY1998 | $3.6B | +7.7% | +$257M | ||
| FY1997 | $3.35B | +8.6% | +$266M | ||
| FY1996 | $3.08B | +20.3% | +$520M | ||
| FY1995 | $2.56B | +29.8% | +$588M | ||
| FY1994 | $1.97B | +116.0% | +$1.06B | ||
| FY1993 | $913M | -36.7% | -$530M | ||
| FY1992 | $1.44B | +15.1% | +$190M | ||
| FY1991 | $1.25B | +19.0% | +$200M | ||
| FY1990 | $1.05B | +8.8% | +$85.6M | ||
| FY1989 | $968M | -4.3% | -$43.7M | ||
| FY1988 | $1.01B | +7.6% | +$71.1M | ||
| FY1987 | $941M | -2.0% | -$18.9M | ||
| FY1986 | $960M | +9.1% | +$79.7M | ||
| FY1985 | $880M | — | — |
- FY2025$15.4B-6.3%
- FY2024$16.5B+211.5%
- FY2023$5.29B-85.9%
- FY2022$37.5B+80.6%
- FY2021$20.8B+128.9%
- FY2020$9.09B+21.0%
- FY2019$7.51B-50.9%
- FY2018$15.3B+6.2%
- FY2017$14.4B+0.8%
- FY2016$14.3B+7.4%
- FY2015$13.3B-5.2%
- FY2014$14B-16.9%
- FY2013$16.9B-6.4%
- FY2012$18B-1.9%
- FY2011$18.4B+3.7%
- FY2010$17.7B+10.8%
- FY2009$16B-3.7%
- FY2008$16.6B+19.4%
- FY2007$13.9B-7.8%
- FY2006$15.1B+3.9%
- FY2005$14.5B-15.0%
- FY2004$17.1B+58.2%
- FY2003$10.8B-12.0%
- FY2002$12.3B+11.9%
- FY2001$11B+26.6%
- FY2000$8.67B+90.6%
- FY1999$4.55B+26.3%
- FY1998$3.6B+7.7%
- FY1997$3.35B+8.6%
- FY1996$3.08B+20.3%
- FY1995$2.56B+29.8%
- FY1994$1.97B+116.0%
- FY1993$913M-36.7%
- FY1992$1.44B+15.1%
- FY1991$1.25B+19.0%
- FY1990$1.05B+8.8%
- FY1989$968M-4.3%
- FY1988$1.01B+7.6%
- FY1987$941M-2.0%
- FY1986$960M+9.1%
- FY1985$880M—
Operating Income values are taken from Pfizer's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current operating income (TTM) is $14.8B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual operating income for Pfizer (PFE) came in at $15.4B – declined 6.3% year-over-year.
Over 2020–2025 (5 years), Pfizer operating income expanded at a +11.2% compound annual rate, with mixed annual results across the window.
Pfizer operating income peaked at $37.5B in 2022; the latest annual figure is $15.4B in 2025 (58.9% below peak).
2022 marks the peak operating income at $37.5B, with the historical low of $880M recorded in 1985.
Pfizer Operating Income by Year
Pfizer Operating Income 2025: $15.4B
Pfizer posted operating income of $15.4B in 2025, declined 6.3% below 2024.
Pfizer Operating Income 2024: $16.5B
In 2024, Pfizer reported operating income of $16.5B, surged 211.5% from 2023.
Pfizer Operating Income 2023: $5.29B
Pfizer operating income in 2023 was $5.29B, plunged 85.9% below 2022.
Pfizer Operating Income 2022: $37.5B
2022's operating income for Pfizer came in at $37.5B, surged 80.6% from 2021. This figure represents the highest annual value in the available history.
Pfizer Operating Income 2021: $20.8B
Pfizer operating income in 2021 was $20.8B.
See more financial history for Pfizer (PFE).
Sector peers by Operating Income
Healthcare peers of Pfizer (PFE), ranked by their latest operating income
| $29.7B | |
| $25.6B | |
| $23.5B | |
| $20.1B | |
| $19.9B | |
| $19B | |
| $10.7B | |
| $8.11B |
- $29.7B
- $25.6B
- $23.5B
- $20.1B
- $19.9B
- $10.7B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks
- Dividend Profile6.84% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.